![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Mayo Clinic National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00602836 |
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving rituximab together with combination chemotherapy and lenalidomide may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with pentostatin, cyclophosphamide, and lenalidomide works in treating patients with previously untreated B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.
Condition | Intervention | Phase |
---|---|---|
Leukemia Lymphoma |
Drug: cyclophosphamide Drug: lenalidomide Drug: pentostatin Drug: rituximab Procedure: flow cytometry Procedure: immunoenzyme technique Procedure: laboratory biomarker analysis Procedure: mutation analysis Procedure: pharmacological study |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab Followed by Consolidation With Lenalidomide for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
Estimated Enrollment: | 45 |
Study Start Date: | February 2008 |
Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Blood samples are collected periodically during treatment for translational and pharmacologic studies. Samples are analyzed for immunoglobulin heavy chain gene mutational status, ZAP-70 status, and levels of VEGF, bFGF, thrombospondin, and TGF-beta by ELISA; and for the effects of therapy on immune function. Samples are also stored for future research. Bone marrow aspirate samples are analyzed for minimal residual disease by flow cytometry.
After completion of study treatment, patients are followed every 90 days for 3 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), meeting the following criteria:
CLL diagnosis* according to NCI working group criteria as evidenced by all of the following:
Immunophenotyping consistent with CLL defined as:
Previously untreated disease and meets ≥ 1 of the following criteria*:
At least 1 or more of the following disease-related symptoms:
PATIENT CHARACTERISTICS:
Total bilirubin ≤ 3.0 times ULN (unless due to Gilbert disease)
No comorbid conditions, including any of the following:
PRIOR CONCURRENT THERAPY:
No concurrent corticosteroids
No concurrent therapeutic doses of coumadin-derivative anticoagulants (e.g., warfarin)
United States, Arizona | |
Mayo Clinic Scottsdale | Recruiting |
Scottsdale, Arizona, United States, 85259-5499 | |
Contact: Clinical Trials Office - All Mayo Clinic Locations 507-538-7623 | |
United States, Florida | |
Mayo Clinic - Jacksonville | Recruiting |
Jacksonville, Florida, United States, 32224 | |
Contact: Clinical Trials Office - All Mayo Clinic Locations 507-538-7623 | |
United States, Minnesota | |
Mayo Clinic Cancer Center | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Clinical Trials Office - All Mayo Clinic Locations 507-538-7623 |
Study Chair: | Tait D. Shanafelt, MD | Mayo Clinic |
Investigator: | Han Win Tun, MD | Mayo Clinic |
Investigator: | Jose F. Leis, MD, PhD | Mayo Clinic Scottsdale |
Investigator: | Neil E. Kay, MD | Mayo Clinic |
Investigator: | Timothy G. Call, MD | Mayo Clinic |
Investigator: | Clive S. Zent, MD | Mayo Clinic |
Investigator: | Diane F. Jelinek, PhD | Mayo Clinic |
Investigator: | Curt Hanson, MD | Mayo Clinic |
Study ID Numbers: | CDR0000582676, MAYO-MC0784, MAYO-07-002156, HOSPIRA-MC0784 |
Study First Received: | January 12, 2008 |
Last Updated: | December 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00602836 |
Health Authority: | Unspecified |
B-cell chronic lymphocytic leukemia stage I chronic lymphocytic leukemia stage II chronic lymphocytic leukemia stage III chronic lymphocytic leukemia stage IV chronic lymphocytic leukemia |
contiguous stage II small lymphocytic lymphoma noncontiguous stage II small lymphocytic lymphoma stage I small lymphocytic lymphoma stage III small lymphocytic lymphoma stage IV small lymphocytic lymphoma |
Chronic lymphocytic leukemia Pentostatin Leukemia, Lymphoid Immunoproliferative Disorders Rituximab Leukemia, B-cell, chronic Lenalidomide |
Cyclophosphamide Leukemia Lymphatic Diseases Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, B-Cell Lymphoproliferative Disorders Lymphoma |
Neoplasms by Histologic Type Immune System Diseases Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors Immunosuppressive Agents |
Pharmacologic Actions Neoplasms Therapeutic Uses Myeloablative Agonists Antineoplastic Agents, Alkylating Antirheumatic Agents Alkylating Agents |